Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Inc (ZNTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Zentalis Pharmaceuticals Inc 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 USA

https://zentalis.com Employees: 166 P: 858-263-4333

Sector:

Medical

Description:

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative breast cancer which is in clinical stage. It operates principally in New York and San Diego. Zentalis Pharmaceuticals, Inc. is based in NEW YORK.

Key Statistics

Overview:

Market Capitalization, $K 101,151
Enterprise Value, $K 67,251
Shares Outstanding, K 72,251
Annual Sales, $ 67,430 K
Annual Net Income, $ -165,840 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -26,690 K
EBIT, $ -161,520 K
EBITDA, $ -164,500 K
60-Month Beta 1.75
% of Insider Shareholders 1.90%
Float, K 70,878
% Float 98.10%
Short Volume Ratio 0.09

Growth:

1-Year Return -55.27%
3-Year Return -92.93%
5-Year Return -97.26%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.37 on 11/10/25
Next Earnings Date 03/25/26
Earnings Per Share ttm -2.07
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 33.93%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ZNTL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -51.49%
Return-on-Assets % -40.00%
Profit Margin % -245.94%
Debt/Equity 0.00
Price/Sales 1.55
Price/Cash Flow N/A
Price/Book 0.41
Book Value/Share 3.51
Interest Coverage -0.90
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar